
Home » Pipeline
Pipeline
Company | Drug/Device | Medical Condition | Status |
---|---|---|---|
COVID-19 Trials and Actions | |||
Genentech | intravenous Actemra (tocilizumab) plus standard of care | hospitalized adult patients with severe COVID-19 pneumonia | initiation of phase 3 trial |
Abbott | RealTime SARS-CoV-2 EUA molecular tests | SARS-CoV-2 | approved by the FDA |
Cepheid | Xpert Xpress SARS-CoV-2 molecular diagnostic test | SARS-CoV-2 | approved by the FDA |
Mesa Biotech | Accula SARS-CoV-2 Test | SARS-CoV-2 | Emergency Use Authorization approved by the FDA |
Bellerophon Therapeutics | inhaled nitric oxide (iNO) delivery system, INOpulse | SARS-CoV-2 | emergency expanded access approved by the FDA |
PerkinElmer | Coronavirus RT-PCR test | SARS-CoV-2 | Emergency Use Authorization approved by the FDA |
Quidel Corporation | Lyra SARS-CoV-2 Assay | SARS-CoV-2 | Emergency Use Authorization approved by the FDA |
Other Trials | |||
Pliant Therapeutics | PLN-1474 | nonalcoholic steatohepatitis (NASH) with liver fibrosis | dosing of first cohort in phase 1 trial |
EOC Pharma | eftilagimod alpha (IMP321) | metastatic breast cancer | completed patient enrollment in phase 1 trial |
Allakos | subcutaneous antolimab (AK002) | healthy subjects | initiation of phase 1 trial |
Inflazome | Inzomelid | Cryopyrin-Associated Periodic Syndrome | completion of phase 1 study |
Ascentage Pharma | APG-2575 in combination with rituximab or acalabrutinib | relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma | dosing of first subject in phase 1b/2 trial |
Allakos | antolimab (AK002) | active, biopsy-confirmed eosinophilic esophagitis | initiation of phase 2/3 trial |
Allakos | antolimab (AK002) | active, biopsy confirmed eosinophilic gastritis and/or eosinophilic duodenitis | initiation of phase 3 trial |
Avadel Pharmaceuticals | FT218 (once-nightly sodium oxybate) | excessive daytime sleepiness and cataplexy in patients with narcolepsy | completion of phase 3 trial |
AgNovos Healthcare | AGN1 Local Osteo-enhancement Procedure (LOEP) Small Volume (SV) Kit | stable vertebral compression fractures | Breakthrough Device designation granted by the FDA |
Prevail Therapeutics | PR006 | to slow the progression of frontotemporal dementia with a GRN mutation (FTD-GRN) | Fast-Track designation granted by the FDA |
AEGEA Medical | Mara Water Vapor Ablation System | heavy menstrual bleeding | approved by the FDA |
Pfizer | Eucrisa (crisaborole) ointment, 2% | children 3 months of age and older with mild-to-moderate atopic dermatitis | sNDA approved by the FDA |
Upcoming Events
-
05Dec
-
14Apr